Why release testing has become a lagging indicator, and what replaces it
How to build process characterization that survives scale, site, and phase changes
We Analyzed FDA’s 2025 Biologics Approvals. Here’s What CMC Teams Need to Do in 2026.
Four Readiness Pillars. Three Executive Case Studies. One Framework for Programs Under Compression.
FDA’s 2025 approval cohort confirms what CMC leaders have felt for two years: engineered modalities are the new baseline, and expedited pathways leave little room to resolve uncertainty late. In that environment, performance is decided by decision quality, not capacity.
This white paper translates the 2025 regulatory signal into four readiness pillars that separate programs holding their pace from programs that stall quietly through investigations, bottlenecks, and transfer rework.
What You'll Learn
Where modelling-enabled agility cuts iteration cost and shortens scale-up
How connected development and digital continuity prevent rationale loss at handoffs
The operating model choices behind a 900% analytical throughput gain and a 400% upstream yield increase